Macular Degeneration Treatment Market (Disease Indication - Dry Age related Macular Degeneration (dAMD), Wet Age-related Macular Degeneration (wAMD); Drug Class - Anti Vascular Endothelial Growth Factor and Others; Distribution Channel - Hospitals, Ophthalmic Clinics, Ambulatory Surgical Centers) - Global Industry Analysis, Size, Share, Growth, Trends, and Forecast 2018 - 2030

Description

Macular Degeneration Treatment Market - Snapshot

The global macular degeneration treatment market was valued at US$ 6.1 Bn in 2017. It is anticipated to reach US$ 11.1 Bn by 2026, expanding at a CAGR of 6.4% from 2018 to 2026. Increase in R&D investments by key players has resulted in innovative products. Increase in prevalence and incidence of retinal disorders, rise in the geriatric population, high annual cost of therapy (ACOT) for pipeline drugs, improved health care as well as health care infrastructure, introduction of novel therapies, and surge in the number of awareness programs are likely to drive the global macular degeneration treatment market during the forecast period. Continued pressure from players mandating the use of Avastin for wAMD and invasive administration methods are anticipated to restrain the global market in the near future. However, developed countries, such as Japan, Germany, the U.S, Canada, France, and Australia offer immense opportunities to the macular degeneration treatment market. This is attributed to the large number of patients, rise in proportion of urban population, and high reimbursement. 

macular degeneration treatment market

The global macular degeneration treatment market has been segmented based on disease indication, drug class, distribution channel, and region. Based on disease indication, the wAMD segment is projected to lead the market, in terms of revenue, and dominate the market during the forecast period, followed by the dAMD segment. Introduction of new anti-VEGF drugs, such as brolucizumab, and less frequent administration regimen in the existing anti-VEGF (Eylea) for treatment of wAMD are estimated to propel the segment. 

In terms of end-user, the global macular degeneration treatment market has been categorized into hospitals, ophthalmic clinics, and ambulatory surgical centers. The hospitals segment accounted for a major share of the global macular degeneration treatment market in 2017. The segment is likely to maintain its leading position during the forecast period. A large population prefers to visit a hospital first rather than an ophthalmic clinic for treatment, as the cost of therapy at a hospital is lower. An ambulatory surgical center is a relatively less preferred option for the treatment of AMD. 

In terms of drugs, the global macular degeneration treatment market has been classified into anti-VEGF and others. The anti-VEGF segment accounted for a major share of the global macular degeneration treatment market in 2017. In 2007, Lucentis became the first anti-VEGF launched for wet AMD as well as other important retinal diseases. It was quickly recognized as the new gold standard for treatment. In 2013, Eylea was also approved for AMD and launched at a marginally lower price; other indications were later added. However, the launch of Novartis’ longer-acting anti-VEGF, brolucizumab is projected to boost the wAMD segment during the forecast period by replacing some use of inexpensive Avastin. 

In terms of region, the global macular degeneration treatment market has been segmented into North America, Europe, Asia Pacific, Latin America, and Middle East & Africa. North America dominated the global macular degeneration treatment market, in terms of revenue, in 2017. It is projected to maintain its dominance during the forecast period. High rate of adoption of prescription AMD disease drugs in the U.S. and increase in the number of approvals for new drugs from the U.S. FDA are major factors responsible for the high share held by North America in 2017. Asia Pacific is anticipated to gain market share during the forecast period owing to a large patient pool, increasing per capita health care expenditure, and increasing investment by key players in this market. 

Major players operating in the global macular degeneration treatment market are Allergan, Inc., Pfizer, Inc., Novartis AG., REGENERON PHARMACEUTICALS, INC., Ophthotech, Santen Pharmaceuticals, Valeant Pharmaceuticals, F. Hoffmann-La Roche Ltd., Sanofi, Ohr Pharmaceutical, Apellis, and Bayer AG. The market is characterized by a large number of acquisitions, which has led to market consolidation and increasing dominance of the top players.

Macular Degeneration Treatment Market - Snapshot

Age-related macular degeneration (MACULAR DEGENERATION) is an eye disease that may get worse over time. It’s the leading cause of severe, permanent vision loss in people over age 60. It happens when the small central portion of your retina, called the macula, wears down. The retina is the light-sensing nerve tissue at the back of your eye. Because the disease happens as you get older, it’s often called age-related macular degeneration. It usually doesn’t cause blindness but might cause severe vision problems. Another form of macular degeneration, called Stargardt disease or juvenile macular degeneration, affects children and young adults.

Macular degeneration treatment breakthroughs inspire hope that someday we may see a cure to this disease.  Promising treatments, described below, depend upon the stage of disease progression. The treatment for early dry macular degeneration is generally nutritional therapy, with a healthy diet high in antioxidants to support the cells of the macula. If macular degeneration is further advanced but still dry, supplements are prescribed, to add higher quantities of certain vitamins and minerals which may increase healthy pigments and support cell structure.

Until recently the only available treatment to seal leaking blood vessels associated with wet macular degeneration was with a laser. The earliest treatment was Laser Photocoagulation. Between 1979 and 1994, the Macular Photocoagulation Study Group conducted a number of clinical trials that enrolled patients with CNV lesions (Choroidal Neovascularization) in one or both eyes. Each affected eye was randomly assigned to either laser treatment or observation. For eligible eyes with CNV in extrafoveal, juxtafoveal and subfoveal locations, laser treatment reduced the risk of severe visual loss.

Unfortunately, even the most successful treatments do not preclude reoccurrence, making multiple treatments likely. However, the rate of vision loss may be slowed down and some sight may be preserved. It is important to understand that this drug is not a cure. At best it preserves the status quo: It will not restore vision that has already been lost.

The global macular degeneration treatment market has been segmented as follows:

Disease Indication

  • Wet age-related macular degeneration
  • Dry age-related macular degeneration
  • Others

Drug Class

  • Anti-vascular endothelial growth factor
  • Others

Distribution Channel

  • Hospitals
  • Ophthalmic Clinics
  • Ambulatory Surgical Centers

Region

  • North America
  • U.S
  • Canada
  • Europe
  • Germany
  • U.K
  • France
  • Italy
  • Spain
  • Rest of Europe
  • Asia Pacific
  • China
  • Japan
  • Australia & New Zealand
  • India
  • Rest of Asia Pacific
  • Latin America
  • Brazil
  • Mexico
  • Rest of Latin America
  • Middle East & Africa
  • GCC
  • South Africa
  • Rest of Middle East & Africa

TABLE OF CONTENT

1. Preface
     1.1. Market Definition and Scope
     1.2. Market Segmentation
     1.3. Key Research Objectives
     1.4. Research Highlights

2. Assumptions and Research Methodology

3. Executive Summary : Global Macular Degeneration Treatment Market

4. Market Overview
     4.1. Introduction
            4.1.1. Disease Indication Definition
            4.1.2. Industry Evolution / Developments
     4.2. Overview
     4.3. Market Dynamics
            4.3.1. Drivers
                      4.3.1.1. Growing prevalence of AMD owing to increase in the geriatric population
                      4.3.1.2. Increase in health care spending and improvement in health care infrastructure
                      4.3.1.3. New product launches and high annual cost of therapy (ACOT)
                      4.3.1.4. Rise in number of eye care centers leading to increased product utilization
            4.3.2. Restraints
                      4.3.2.1. Patent expiry of three well-established anti-VEGFs
                      4.3.2.2. Non-compliance with treatment
                      4.3.2.3. Lack of awareness 
            4.3.3. Opportunities
     4.4. Global Macular Degeneration Treatment Market Analysis and Forecast, 2016–2026
            4.4.1. Market Revenue Projections (US$ Mn)

5. Key Insight
     5.1. Regulatory Scenario by Region/Globally
     5.2. Key Mergers & Acquisitions
     5.3. AMD Clinical Trial Analysis
     5.4. Reimbursement Scenario 
     5.5. AMD Prevalence Rate Globally with Key Countries

6. Global Macular Degeneration Treatment Market Analysis and Forecast, by Disease Indication 
     6.1. Introduction & Definition
     6.2. Key Findings / Developments
     6.3. Global Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
            6.3.1. Wet age-related macular degeneration
            6.3.2. Dry age-related macular degeneration
            6.3.3. Others
     6.4. Global Macular Degeneration Treatment Market Attractiveness, by Disease Indication 

7. Global Macular Degeneration Treatment Market Analysis and Forecast, by Drug Class 
     7.1. Introduction & Definition
     7.2. Key Findings / Developments
     7.3. Global Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
            7.3.1. Anti-vascular endothelial growth factor
            7.3.2. Others
     7.4. Global Macular Degeneration Treatment Market Attractiveness, by Drug Class

8. Global Macular Degeneration Treatment Market Analysis and Forecast, by Distribution Channel 
     8.1. Introduction & Definition
     8.2. Key Findings / Developments     
     8.3. Global Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
            8.3.1. Hospitals
            8.3.2. Ophthalmic Clinics
            8.3.3. Ambulatory Surgical Centers     
     8.4. Global Macular Degeneration Treatment Market Attractiveness, by Distribution Channel 

9. Global Macular Degeneration Treatment Market Analysis and Forecast, by Region
     9.1. Key Findings
     9.2. Global Macular Degeneration Treatment Market Value Forecast, by Region
            9.2.1. North America 
            9.2.2. Europe 
            9.2.3. Asia Pacific 
            9.2.4. Latin America 
            9.2.5. Middle East & Africa 
     9.3. Global Macular Degeneration Treatment Market Attractiveness, by Region

10. North America Macular Degeneration Treatment Market Analysis and Forecast
     10.1. Introduction
            10.1.1. Key Findings
     10.2. North America Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
            10.2.1. Wet age-related macular degeneration
            10.2.2. Dry age-related macular degeneration
            10.2.3. Others
     10.3. North America Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
            10.3.1. Anti-vascular endothelial growth factor
            10.3.2. Others
     10.4. North America Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
            10.4.1. Hospitals
            10.4.2. Ophthalmic Clinics
            10.4.3. Ambulatory Surgical Centers
     10.5. North America Macular Degeneration Treatment Market Value Forecast, by Country, 2016–2026
            10.5.1. U.S.
            10.5.2. Canada
     10.6. North America Macular Degeneration Treatment Market Attractiveness Analysis 
            10.6.1. By Disease Indication 
            10.6.2. By Drug Class
            10.6.3. By Distribution Channel 
            10.6.4. By Country

11. Europe Macular Degeneration Treatment Market Analysis and Forecast
     11.1. Introduction
            11.1.1. Key Findings
     11.2. Europe Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
            11.2.1. Wet age-related macular degeneration
            11.2.2. Dry age-related macular degeneration
            11.2.3. Others
     11.3. Europe Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
            11.3.1. Anti-vascular endothelial growth factor
            11.3.2. Others
     11.4. Europe Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
            11.4.1. Hospitals
            11.4.2. Ophthalmic Clinics
            11.4.3. Ambulatory Surgical Centers
     11.5. Europe Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
            11.5.1. Germany
            11.5.2. U.K.
            11.5.3. France
            11.5.4. Spain
            11.5.5. Italy
            11.5.6. Rest of Europe
     11.6. Europe Macular Degeneration Treatment Market Attractiveness Analysis 
            11.6.1. By Disease Indication 
            11.6.2. By Drug Class
            11.6.3. By Distribution Channel 
            11.6.4. By Country/Sub-region

12. Asia Pacific Macular Degeneration Treatment Market Analysis and Forecast
     12.1. Introduction
            12.1.1. Key Findings
     12.2. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
            12.2.1. Wet age-related macular degeneration
            12.2.2. Dry age-related macular degeneration
            12.2.3. Others
     12.3. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
            12.3.1. Anti-vascular endothelial growth factor
            12.3.2. Others
     12.4. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
            12.4.1. Hospitals
            12.4.2. Ophthalmic Clinics
            12.4.3. Ambulatory Surgical Centers
     12.5. Asia Pacific Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
            12.5.1. China
            12.5.2. Japan
            12.5.3. India
            12.5.4. Australia & New Zealand
            12.5.5. Rest of Asia Pacific
     12.6. Asia Pacific Macular Degeneration Treatment Market Attractiveness Analysis 
            12.6.1. By Disease Indication 
            12.6.2. By Drug Class
            12.6.3. By Distribution Channel 
            12.6.4. By Country/Sub-region

13. Latin America Macular Degeneration Treatment Market Analysis and Forecast
     13.1. Introduction
            13.1.1. Key Findings     
     13.2. Latin America Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
            13.2.1. Wet age-related macular degeneration
            13.2.2. Dry age-related macular degeneration
            13.2.3. Others     
     13.3. Latin America Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
            13.3.1. Anti-vascular endothelial growth factor
            13.3.2. Others
     13.4. Latin America Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
            13.4.1. Hospitals
            13.4.2. Ophthalmic Clinics
            13.4.3. Ambulatory Surgical Centers
     13.5. Latin America Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
            13.5.1. Brazil
            13.5.2. Mexico
            13.5.3. Rest of Latin America
     13.6. Latin America Macular Degeneration Treatment Market Attractiveness Analysis 
            13.6.1. By Disease Indication 
            13.6.2. By Drug Class
            13.6.3. By Distribution Channel 
            13.6.4. By Country/Sub-region

14. Middle East & Africa Macular Degeneration Treatment Market Analysis and Forecast
     14.1. Introduction
            14.1.1. Key Findings
     14.2. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Disease Indication, 2016–2026
            14.2.1. Wet age-related macular degeneration
            14.2.2. Dry age-related macular degeneration
            14.2.3. Others
     14.3. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Drug Class, 2016–2026
            14.3.1. Anti-vascular endothelial growth factor
            14.3.2. Others
     14.4. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Distribution Channel, 2016–2026
            14.4.1. Hospitals
            14.4.2. Ophthalmic Clinics
            14.4.3. Ambulatory Surgical Centers
     14.5. Middle East & Africa Macular Degeneration Treatment Market Value Forecast, by Country/Sub-region, 2016–2026
            14.5.1. GCC Countries
            14.5.2. South Africa
            14.5.3. Rest of Middle East & Africa
     14.6. Middle East & Africa Macular Degeneration Treatment Market Attractiveness Analysis 
            14.6.1. By Disease Indication 
            14.6.2. By Drug Class
            14.6.3. By Distribution Channel 
            14.6.4. By Country/Sub-region

15. Competition Landscape
     15.1. Market Player – Market Share Analysis by Company & Competition Matrix (By Tier and Size of companies)
     15.2. Company Profiles
            15.2.1. Allergan plc.
                      15.2.1.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                      15.2.1.2. Business Overview
                      15.2.1.3. Product Portfolio 
                      15.2.1.4. Financial Overview 
                      15.2.1.5. SWOT Analysis 
            15.2.2. Novartis AG 
                      15.2.2.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                      15.2.2.2. Business Overview
                      15.2.2.3. Product Portfolio 
                      15.2.2.4. Financial Overview 
                      15.2.2.5. SWOT Analysis 
            15.2.3. Pfizer Inc. 
                      15.2.3.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                      15.2.3.2. Business Overview
                      15.2.3.3. Product Portfolio 
                      15.2.3.4. Financial Overview 
                      15.2.3.5. SWOT Analysis 
            15.2.4. Santen Pharmaceuticals Co. Ltd.
                      15.2.4.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                      15.2.4.2. Business Overview
                      15.2.4.3. Product Portfolio 
                      15.2.4.4. Financial Overview 
                      15.2.4.5. SWOT Analysis 
            15.2.5. Valeant Pharmaceuticals International, Inc.
                      15.2.5.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                      15.2.5.2. Business Overview
                      15.2.5.3. Product Portfolio 
                      15.2.5.4. Financial Overview 
                      15.2.5.5. SWOT Analysis 
            15.2.6. Bayer AG 
                      15.2.6.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                      15.2.6.2. Business Overview
                      15.2.6.3. Product Portfolio 
                      15.2.6.4. Financial Overview 
                      15.2.6.5. SWOT Analysis 
            15.2.7. F. Hoffmann-La Roche Ltd.
                      15.2.7.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                      15.2.7.2. Business Overview
                      15.2.7.3. Product Portfolio 
                      15.2.7.4. Financial Overview 
                      15.2.7.5. SWOT Analysis 
            15.2.8. Sanofi
                      15.2.8.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                      15.2.8.2. Business Overview
                      15.2.8.3. Product Portfolio 
                      15.2.8.4. Financial Overview 
                      15.2.8.5. SWOT Analysis 
            15.2.9. REGENERON PHARMACEUTICALS, INC.
                      15.2.9.1. Company Overview (Headquarters, Business Segments, Employee Strength)
                      15.2.9.2. Business Overview
                      15.2.9.3. Product Portfolio 
                      15.2.9.4. Financial Overview 
                      15.2.9.5. SWOT Analysis 

Choose License Type

Checkout Inquiry Sample